3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Colorectal Neoplasms
2
Small Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Locally Advanced Cervical Cancer
1
Esophageal Neoplasms
1
Breast Neoplasms
1
Atrial Fibrillation
1
Interventions
Carboplatin
11
atezolizumab
10
Etoposide
9
durvalumab
6
Topotecan
6
PM 01183
6
Specimen Handling
4
pembrolizumab
3
Magnetic Resonance Spectroscopy
3
Irinotecan
2
Injections
2
Drug Therapy
2
Cisplatin
2
Biopsy
2
AMG 757
2
tremelimumab
1
trastuzumab deruxtecan
1
toripalimab
1
olaparib
1
lenvatinib
1
fludarabine
1
enzalutamide
1
cabozantinib
1
berzosertib
1
avelumab
1
arginine decarboxylase
1
amrubicin
1
Vaccines
1
Taxes
1
Sodium Chloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
Sodium Chloride
×
30 days
×
Clear all
NCT04624204
2026-05-26
MK 7339-013
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
672 enrolled